morpholinoanthracycline mx2 has been researched along with Neoplasm Metastasis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Basser, RL; Cebon, J; Clarke, K; Geldard, H; Green, MD; Hill, JS; Kaye, AH; Maher, DW; Morgan, DJ; Park, SJ; Stylli, SS | 1 |
| Abe, O; Adachi, I; Enomoto, K; Kajiwara, T; Katsumata, N; Kusama, M; Ogawa, M; Tominaga, T; Watanabe, T; Yamada, Y | 1 |
2 trial(s) available for morpholinoanthracycline mx2 and Neoplasm Metastasis
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Area Under Curve; Carubicin; Doxorubicin; Female; Half-Life; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Neutropenia; Neutrophils; Safety | 1997 |
Phase II study of KRN8602, 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin hydrochloride, MX2 x HCl in patients with metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Carubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis | 1999 |